Related Experiment Video
Updated: Dec 18, 2025
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo
Xiulong Zhong1, Hong Xiu2, Yanan Bi2
1Department of Urology, The Affiliated Hospital of Qingdao University , Qingdao, Shandong, China.
Abstract:
Overexpression of eukaryotic initiation factor- 5A2 (eIF5A2) has been implicated in promoting tumor cell migration and invasion in many cancers. However, whether eIF5A2 could be as the target for prostate cancer (PCa) treatment is still unknown. In this study, small interfering RNA specific for eIF5A2 (eIF5A2 siRNA) and lentivector for eIF5A2 shRNA (Lv-eIF5A2 shRNA) was performed to down-regulate eIF5A2 expression in PCa PC-3 M IE8 cells and in animal tumor model, respectively. The biological function of eIF5A2 siRNA or Lv-eIF5A2 shRNA on PC-3 M IE8 cell growth, apoptosis, migration, invasion and lung metastasis were explored. The results showed that targeting eIF5A2 inhibited PC-3 M IE8 cell invasion, migration, proliferation and increased cell apoptosis in vitro, and inhibited tumor growth and lung metastasis in vivo. Analysis of eIF5A2 signaling pathways in the clonal derivatives showed a decrease in MMP-2 and MMP-9 activation and increase in bcl-2 expression. We therefore concluded that therapies targeting the eIF5A2 signaling pathway may be more effective to prevent organ metastasis and primary tumor formation.
Insights
Targeting eukaryotic initiation factor-5A2 (eIF5A2) effectively suppressed prostate cancer cell invasion, migration, and growth. This study demonstrates eIF5A2 as a promising therapeutic target for inhibiting prostate cancer metastasis and tumor formation.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Overexpression of eukaryotic initiation factor-5A2 (eIF5A2) is linked to tumor cell migration and invasion in various cancers.
- The role of eIF5A2 in prostate cancer (PCa) progression and its potential as a therapeutic target remain largely unexplored.
Purpose of the Study:
- To investigate the therapeutic potential of targeting eIF5A2 in prostate cancer.
- To evaluate the effects of down-regulating eIF5A2 on PCa cell behavior and tumor growth.
Main Methods:
- Utilized small interfering RNA (siRNA) for eIF5A2 (eIF5A2 siRNA) in PCa cells (PC-3M IE8) and a lentiviral vector for eIF5A2 shRNA (Lv-eIF5A2 shRNA) in an animal tumor model.
- Assessed the impact of eIF5A2 down-regulation on cell proliferation, apoptosis, migration, invasion, and lung metastasis.
- Analyzed alterations in key signaling pathways, including MMP-2, MMP-9, and bcl-2 expression.
Main Results:
- Down-regulation of eIF5A2 significantly inhibited PC-3M IE8 cell invasion, migration, and proliferation in vitro.
- Targeting eIF5A2 led to increased apoptosis in PCa cells in vitro.
- In vivo studies showed that inhibiting eIF5A2 suppressed tumor growth and reduced lung metastasis.
- Reduced activation of MMP-2 and MMP-9, along with increased bcl-2 expression, was observed in response to eIF5A2 targeting.
Conclusions:
- Therapies targeting the eIF5A2 signaling pathway demonstrate significant potential for preventing prostate cancer metastasis and primary tumor formation.
- eIF5A2 represents a viable molecular target for developing novel prostate cancer treatments aimed at controlling tumor spread.
